Physician profile
James Vu
NPI 1790210797
$1,218.58
in general payments reported to CMS, 2019-2025
18 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $249 · 2021: $247 · 2022: $37.16 · 2023: $141 · 2024: $19.45 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $298.49 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Allergan, INC. | $127.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $124.12 | 2023 | Spravato |
| Exact Sciences Corporation | $81.28 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $57.88 | 2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $57.27 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.53 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $47.19 | 2025 | Voquezna |
| Intuitive Surgical, INC. | $37.16 | 2022 | |
| Lilly USA, LLC | $35.61 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $34.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.79 | 2025 | Caplyta |
| Metacel Pharmaceuticals LLC | $24.61 | 2025 | Ozobax |
| Abbott Laboratories | $20.46 | 2025 | Freestyle Libre |
| Philips North America LLC | $16.87 | 2025 | Extended Holter |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $16.41 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals Lp | $16.22 | 2025 | Breztri |
| Abbvie INC. | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.